Seer rais­es an­oth­er $55M and fi­nal­ly re­veals pro­teom­ic tech — can it hold up?

Two years ago, Omid Farokhzad left his promi­nent nano-med­i­cine lab at Boston’s Brigham and Women’s Hos­pi­tal and moved across the coun­try to found a start­up off tech­nol­o­gy that, he said, could change the field of pro­teomics — and, with it, parts of med­i­cine, agri­cul­ture and a range of fields.

To­day, Farokhzad has fi­nal­ly re­vealed what that tech­nol­o­gy is. In a Na­ture Com­mu­ni­ca­tions pa­per, he showed how his com­pa­ny, Seer, and their lead prod­uct, called the Pro­teo­graph, can use nanopar­ti­cles to an­a­lyze the pro­tein com­po­si­tions in a sin­gle blood sam­ple, like a fish­ing net web­bing the con­tents of a par­tic­u­lar swath of sea. Or — to use the com­pa­ny’s pre­ferred metaphor — like a se­quenc­ing ma­chine read­ing out the base pairs on a par­tic­u­lar strand of DNA.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER